Alexander Edward Kuta III Sells 2,229 Shares of uniQure (NASDAQ:QURE) Stock

uniQure (NASDAQ:QURE) VP Alexander Edward Kuta III sold 2,229 shares of the business’s stock in a transaction that occurred on Tuesday, September 21st. The stock was sold at an average price of $36.71, for a total value of $81,826.59. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Alexander Edward Kuta III also recently made the following trade(s):

  • On Wednesday, September 15th, Alexander Edward Kuta III sold 6,000 shares of uniQure stock. The stock was sold at an average price of $36.32, for a total transaction of $217,920.00.
  • On Monday, August 16th, Alexander Edward Kuta III sold 6,000 shares of uniQure stock. The stock was sold at an average price of $28.84, for a total transaction of $173,040.00.
  • On Thursday, July 15th, Alexander Edward Kuta III sold 6,000 shares of uniQure stock. The stock was sold at an average price of $27.22, for a total value of $163,320.00.

Shares of NASDAQ QURE traded up $1.58 during midday trading on Tuesday, reaching $38.20. The company’s stock had a trading volume of 24,879 shares, compared to its average volume of 494,378. The company has a debt-to-equity ratio of 0.11, a quick ratio of 15.06 and a current ratio of 15.06. The company has a market cap of $1.76 billion, a P/E ratio of 6.06 and a beta of 1.22. The business’s 50 day moving average price is $30.05 and its two-hundred day moving average price is $31.95. uniQure has a fifty-two week low of $25.80 and a fifty-two week high of $52.19.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Sunday, July 25th. The biotechnology company reported $8.51 EPS for the quarter, topping the Zacks’ consensus estimate of $2.97 by $5.54. The firm had revenue of $463.87 million for the quarter, compared to analyst estimates of $212.65 million. uniQure had a return on equity of 90.98% and a net margin of 60.66%. Sell-side analysts forecast that uniQure will post 6.23 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of QURE. Virtu Financial LLC bought a new stake in uniQure during the second quarter worth about $710,000. Marshall Wace LLP bought a new stake in shares of uniQure during the 2nd quarter worth approximately $2,262,000. Marshall Wace North America L.P. bought a new stake in shares of uniQure during the 2nd quarter worth approximately $5,489,000. Morgan Stanley boosted its position in shares of uniQure by 114.4% during the 2nd quarter. Morgan Stanley now owns 105,734 shares of the biotechnology company’s stock worth $3,256,000 after acquiring an additional 56,427 shares in the last quarter. Finally, Sphera Funds Management LTD. bought a new position in uniQure in the second quarter valued at approximately $5,298,000. Institutional investors own 77.06% of the company’s stock.

QURE has been the subject of several research analyst reports. Zacks Investment Research upgraded uniQure from a “sell” rating to a “hold” rating in a research note on Friday, July 30th. Chardan Capital reiterated a “buy” rating and issued a $95.00 price objective (down from $100.00) on shares of uniQure in a report on Tuesday, July 27th. Credit Suisse Group restated an “outperform” rating and set a $27.46 target price (down previously from $78.00) on shares of uniQure in a research note on Tuesday, July 27th. SVB Leerink reiterated a “buy” rating on shares of uniQure in a research note on Tuesday, September 14th. Finally, BTIG Research initiated coverage on shares of uniQure in a research report on Monday, June 14th. They set a “buy” rating and a $46.00 price objective for the company. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $59.95.

uniQure Company Profile

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Recommended Story: Is it Safe to Invest in Commodities?

Insider Buying and Selling by Quarter for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.